Nkarta

-$0.36 (-2.61%) As of 12:49 PM UTC pre-market

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Nkarta and other ETFs, options, and stocks.

About NKTX

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells.

CEO
Paul J. Hastings
Employees
136
Headquarters
South San Francisco, California
Founded
2005

NKTX Key Statistics

Market cap
668.46M
Price-Earnings ratio
—
Dividend yield
—
Average volume
1.45M
High today
$14.50
Low today
$13.46
Open price
$13.72
Volume
760.52K
52 Week high
$40.64
52 Week low
$7.55

NKTX Earnings

-$0.90
-$0.60
-$0.30
-$0.00
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Estimated
— per share
Actual
-$0.79 per share
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure